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preclinical dosimetry models 
and the prediction of clinical 
doses of novel positron emission 
tomography radiotracers
Adam A. Garrow1, Jack p. M. Andrews2, Zaniah n. Gonzalez1,2, carlos A. corral1,2, 
christophe portal3, timaeus e. f. Morgan1,2, tashfeen Walton1,2, ian Wilson3, 
David e. newby1,2, christophe Lucatelli1 & Adriana A. S. tavares1,2*
Dosimetry models using preclinical positron emission tomography (pet) data are commonly 
employed to predict the clinical radiological safety of novel radiotracers. However, unbiased clinical 
safety profiling remains difficult during the translational exercise from preclinical research to first-
in-human studies for novel PET radiotracers. In this study, we assessed PET dosimetry data of six 
18F-labelled radiotracers using preclinical dosimetry models, different reconstruction methods and 
quantified the biases of these predictions relative to measured clinical doses to ease translation of 
new PET radiotracers to first-in-human studies. Whole-body PET images were taken from rats over 
240 min after intravenous radiotracer bolus injection. Four existing and two novel PET radiotracers 
were investigated:  [18f]fDG,  [18F]AlF-NOTA-RGDfK,  [18F]AlF-NOTA-octreotide  ([18F]AlF-NOTA-OC), 
 [18F]AlF-NOTA-NOC,  [18F]ENC2015 and  [18F]ENC2018. Filtered-back projection (FBP) and iterative 
methods were used for reconstruction of pet data. predicted and true clinical absorbed doses for  [18f]
fDG and  [18F]AlF-NOTA-OC were then used to quantify bias of preclinical model predictions versus 
clinical measurements. our results show that most dosimetry models were biased in their predicted 
clinical dosimetry compared to empirical values. therefore, normalization of rat:human organ sizes 
and correction for reconstruction method biases are required to achieve higher precision of dosimetry 
estimates.
In positron emission tomography (PET) imaging, it is central to human safety that the dosimetry profile of a novel 
radiotracer is accurately determined from a robust preclinical model. The radiation dose is then translated to 
predict the amount of ionising radiation that would be experienced by human subjects prior to the radiotracer’s 
clinical use. This is one of several steps to achieve success for the clinical translation of new  radiotracers1. 
However, the limited understanding of which preclinical model is the least biased for the prediction of novel 
radiotracer dosimetry profiles in first-in-human studies increases attrition in the decision-making process from 
preclinical to clinical translation of novel PET radiotracers.
There are several possible causes for the inconsistencies between predictive and empirical clinical dosimetry 
when determining the radiation safety of a newly developed PET radiotracer. The preclinical and clinical bio-
distribution of a given PET radiotracer may vary drastically due to a range of factors: inter-species differences in 
metabolic rates for the same radiotracer and differences in anatomical hierarchies in preclinical species compared 
to  humans2. In addition, computer modelling software using preclinical in vivo dosimetry measurements may 
not account for the heterogeneous nature of organ arrangements, shapes and  densities3.
Predictive dosimetry models that do not address one or several of these factors regularly show either signifi-
cant over- or underestimation of both effective and absorbed organ dosing from PET  radiotracers4. Differences in 
metabolism and anatomical barriers can be challenging to predict and minimise. Notwithstanding, it is possible 
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to improve preclinical predictive dosimetry models if the known inaccuracies result from systematically model-
ling over- or underestimations, rather than unpredictable spurious causes. Mitigation of these causes could help 
minimise further lapses in the predictive ability of preclinical dosimetry models and improve the success rate of 
early-stage clinical trials for novel radiotracers.
A particularly compelling case for the development of better methods for clinical dosimetry estimates from 
preclinical data is PET imaging using peptide-based radiotracers. These peptides are known to often present 
adverse kidney kinetics, as the kidneys are commonly a primary clearing site via glomerular  filtration5, resulting 
at times in prohibitive radiation dosimetry profiles for in-human translation. In the current era of  theranostics6,7, 
accessible generator-based PET radionuclide  production8,9, efficient and inexpensive 18F-labelling  methods10 
and an expanding arsenal of peptide PET  radiotracers11–13, there is a need to identify rapidly and confidently 
lead radiotracer candidates for first-in-human translation. Therefore, the optimization of preclinical dosimetry 
models to improve the prediction of clinical doses of novel PET radiotracers is required.
In this study we aimed to quantify the absorbed dose from six fluorinated PET radiotracers with different 
biochemical properties and quantify biases introduced from distinct preclinical dosimetry models. We deter-
mined if any mathematical relationships between the biases introduced by methods for preclinical predictions 
of clinical dosimetry exist independently of the administered radiotracer and whether these relationships can 
be used to optimise future dosimetry estimates of novel PET radiotracers.
Results
Biodistribution and dosimetry comparison across six different PET radiotracers. Representa-
tive PET images of each radiotracer biodistributions are displayed in Fig. 1 (iterative reconstruction method) 
and Supplementary Figure 2 (FBP reconstruction method with correspondent time-activity curves shown in 
Supplementary Figure 3).The highest  [18F]FDG uptake was observed, as expected, in the brain, heart, kidneys 
and urinary bladder. For the peptide-based radiotracers, the highest uptake was observed in the kidneys and 
appeared from highest to lowest in  [18F]ENC2015 and  [18F]ENC2018, then  [18F]AlF-NOTA-NOC and  [18F]
AlF-NOTA-OC and finally  [18F]AlF-NOTA-RGDfK.
Residence times of radiotracers in all source organs and remaining compartment differed significantly by 
radiotracer except for the residence times of the intestine obtained from FBP reconstructions. All peptide-based 
radiotracers had significantly lower τ in the brain, heart, lungs and liver regardless of the reconstruction method 
used compared with  [18F]FDG. Conversely, apart from  [18F]AlF-NOTA-RGDfK, all peptide-based radiotracers 
had significantly higher τ in the kidneys compared with  [18F]FDG. Residence times in the urinary bladder were 
similar for all six radiotracers used in this study (Supplementary Tables 2‒4). Organ absorbed doses and whole-
body effective doses for all six PET radiotracers are summarised in Supplementary Tables 5‒12.
The dosimetry models using PET data reconstructed with FBP consistently predicted the urinary bladder, 
followed by the lower large intestinal (LLI) wall and kidneys, as the organs receiving the highest absorbed doses 
from  [18F]FDG, independent of the phantom’s sex and normalisation of organ masses to human equivalents 
(Supplementary Tables 5–8). Conversely, dosimetry estimates using iterative-reconstructed PET data had more 
variability in the highly-dosed organs, with ranking order of LLI wall, kidneys and bladder changing depend-
ing on phantom and normalisation strategy used (Supplementary Tables 9–12). The dosimetry models yielded 
more consistent results for  [18F]RGD than  [18F]FDG; and all models predicted the top three absorbed organ 
doses to be in the urinary bladder > LLI wall > kidneys, except for the iterative normalised adult male model 
whose predicted ordering of highest absorbed organ doses was to the urinary bladder > kidneys > LLI wall. For 
both  [18F]AlF-NOTA-NOC and  [18F]AlF-NOTA-OC, all dosimetry models predicted the highest doses to be 
Figure 1.  Representative Maximum Intensity Projection (MIP) of SUV PET images (0–2 g/mL) of radiotracer 
biodistribution in rats. Biodistribution of (a)  [18F]FDG, (b)  [18F]AlF-NOTA-RGDfK, (c)  [18F]AlF-NOTA-NOC, 
(d)  [18F]AlF-NOTA-OC, (e)  [18F]ENC2015 and (f)  [18F]ENC2018.
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absorbed by the urinary bladder > LLI wall > kidneys, except the normalised iterative dosimetry models whose 
rankings were urinary bladder > kidneys > LLI wall. The predicted highest absorbed doses from  [18F]ENC2015 
were mixed depending on the dosimetry model; either the kidneys or urinary bladder were predicted to absorb 
the two highest doses across the models, but all models predicted the LLI wall to absorb the third-highest dose 
from this radiotracer. Finally,  [18F]ENC2018 was unanimously predicted by the models to most heavily dose the 
kidneys, then the urinary bladder and then the LLI wall.
impact of pet reconstruction method and residence times’ normalisation on estimated 
absorbed doses. The iterative reconstruction method provided higher source organ residence time esti-
mates than the FBP method (Fig. 2); and normalising the source organ masses of rats to male or female human 
equivalents did not significantly affect the ratio of the residence times estimated from FBP and iterative recon-
structions (non-normalised: r2 = 0.9148;  F1,159 = 1707; Mean = 1.611; 95% CI slope = 1.534, 1.687|normalised 
to adult male: r2 = 0.9101;  F1,159 = 1609; Mean = 1.617; 95% CI slope = 1.538, 1.696|normalised to adult female: 
r2 = 0.9183;  F1,205 = 1787; Mean = 1.590; 95% CI slope = 1.517, 1.664).
Given that the kidneys were predominately the main elimination route for all radiotracers and the criti-
cal organs for all six radiotracers included in this study, additional comparative analysis of predicted kidney 
absorbed doses was conducted alongside whole-body effective doses (Fig. 3). Data shows that both reconstruc-
tion methods and normalisation methods can have a statistically significant impact on absorbed dose estimates, 
but this effect is diluted when assessing whole-body effective doses. Differences across kidney absorbed doses 
for multiple radiotracers were less prominent when using FBP (Fig. 3a, b) compared with iterative (Fig. 3c, d) 
methods of reconstruction.
Quantitative bias associated with preclinical prediction of clinical dosimetry of two pet radi-
otracers. [18F]FDG bias of the preclinical dosimetry models using FBP and non-normalised τ were overesti-
mated compared with clinically measured dosimetry values and were lower for the male than the female phan-
tom. Conversely, absorbed doses calculated using normalised τ and FBP methods were underestimated versus 
clinically measured values, and these were lower for the female than the male phantom. The same bias trend was 
observed when using PET data reconstructed with iterative methods, except the bias was substantially amplified 
compared with FBP (Fig. 4a, Table 1 and Supplementary Figure 4a). Interestingly, these quantitative bias trends 
associated with preclinical prediction of clinical dosimetry, as a function of reconstruction method and nor-
malised/non-normalised τ approach, measured with  [18F]FDG (Fig. 4a, Table 1 and Supplementary Figure 4a) 
were identical to  [18F]AlF-NOTA-OC (Fig. 4b, Table 1 and Supplementary Figure 4b) PET data. Bland–Altman 
plots assessing agreement between the two methods can be seen in Figs. 5 and 6. These show there was overall a 
good agreement between preclinical predictions and clinically measured doses with the kidneys as main outliers.
When the LLI wall was included in the bias quantification analyses, all dosimetry models for predicting 
clinical absorbed organ doses of  [18F]FDG (Supplementary Figure 4a) and  [18F]AlF-NOTA-OC (Supplemen-
tary Figure 4b) were less precise than their respective counterparts that excluded the LLI wall from the bias 
quantification (Fig. 4 and Table 1). Across all tested dosimetry models, there was a range of 1.001 to 3.054 times 
Figure 2.  Comparison of residence times measured using FBP and iterative methods of reconstruction. Linear 
regression lines plotted using residence times measured for all source organ of all six radiotracers  ([18F]FDG, 
 [18F]AlF-NOTA-RGDfK,  [18F]AlF-NOTA-NOC,  [18F]ENC2015 and  [18F]ENC2018).
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improvement in their precision when the LLI wall was excluded from bias quantification. Bland–Altman plots 
assessing agreement between the two methods can be seen in Supplementary Figures 5 and 6.
Discussion
In this study we report the dosimetry estimates for six different PET radiotracers using a preclinical rodent 
model. Our results showed that the choice of methods used for PET data reconstruction can impact dosimetry 
estimates of 18F-labelled radiotracers, where the τ values determined with iterative methods were approximately 
50% higher than the τ values determined with FBP. Moreover, FBP OLINDA estimates were more consistent 
and less biased than those obtained with iterative reconstruction methods. Consequently, the use of FBP for 
reconstruction of preclinical PET data for dosimetry estimates is preferred.
Although the impact of reconstruction methods on radionuclide dose estimates has been sparsely investigated 
in previous  clinical14,15 and  preclinical16 studies, there is little understanding of the mathematical relationships of 
this bias and whether it is due to systematic errors or random and radiotracer-dependent differences. The results 
of the six radiotracers used in this study show a significant and strong linear relationship between predicted clini-
cal dosimetry from preclinical models versus clinical models when using FBP and rat:human normalised data. 
Regardless of the radiotracer, there was always an underestimation of the predicted dose by a mean value of 42% 
(range 22–58%). Consequently, this mathematical relationship and simplified underestimation correction factor 
can be conveniently used to optimise future dosimetry estimates of novel PET radiotracers in a systematic man-
ner. It is also encouraging to observe that the underestimation bias measured with 18F-labelled radiotracers was 
also previously reported by others using a radiotracer labelled with copper-6416. This suggests the mathematical 
Figure 3.  Whole-body effective doses and absorbed kidney doses, estimated using different methods of 
reconstruction and organ normalization strategies for all six PET radiotracers included in this study. (a) 
Doses from FBP reconstructions using non-normalised residence times, (b) FBP reconstructions using 
normalised residence times, (c) iterative reconstructions using non-normalised residence times and (d) 
iterative reconstructions using normalised residence times. Data presented as Mean ± SEM. One-way analysis of 
variants and Dunnett’s multiple comparison test  ([18F]FDG as control group). Legend: ENC15 = [18F]ENC2015, 
ENC18 = [18F]ENC2018, FDG = 2-deoxy-2-[18F]fluoro-d-glucose, NOC = [18F]AlF-NOTA-NOC, OC = [18F]AlF-
NOTA-OC, RGD = [18F]AlF-NOTA-RGDfK.
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relationships observed in this dosimetry study may persist in a broader nuclear medicine context and likely for 
different radioisotopes, including for example alpha and beta emitters used in radiation therapy studies, thus, 
representing a systematic error in PET dosimetry calculations based on preclinical models.
Normalization of rodent:human17,18, non-human primate:human19–21 and pig:human17 organ sizes has been 
previously used to estimate PET dosimetry of new radiotracers. Many studies focus on developing preclinical 
models of animal dosimetry (see  review22) and well-established human PET dosimetry  models23,24. Unfortunately, 
dichotomous dosimetry findings are prevalent when translating a novel radiotracer from preclinical research to 
clinical use, which is likely a result of an important knowledge gap of the bias between preclinical dose estimates 
and human doses. To circumvent this gap, the combined use of FBP, normalised organ data and application of 
the bias correction factor, as proposed in this research, represent an optimised model for translation of novel 
PET radiotracers to the clinic.
Results from this study also demonstrate that when the optimised dosimetry estimation model is applied, 
administration of  [18F]AlF-NOTA-RGDfK will result in similar radiation dose to administration of  [18F]FDG. 
The octreotide analogues would result in approximately twice the radiation dose to the kidneys and the novel 
radiotracers ENC2015 and ENC2018 would result in 20‒40 times higher kidney dose compared with  [18F]FDG. 
The use of two octreotide analogues and two factor XIIIa analogue radiotracers also highlight the importance 
of carefully assessing dosimetry estimates for each radiotracer analogue prior to translation to humans, even if 
only small molecular structure changes are introduced.
Results from this work have direct real-world applications by setting an approach to reconstruct PET data and 
calculate acceptable safe dosimetry confidence intervals when translating novel PET radiotracers from animal 
research to clinical use, thus enabling efficient de-prioritization of radiotracers with suboptimal dosimetry values.
Although preclinical species are required for the early development of novel PET radiotracers and they can be 
used as models for estimation of human dosimetry, anatomical differences can be hard to circumvent. However, 
these differences can be minimised. For example, we observed increased precision across all dosimetry models 
with removal of the LLI wall from the bias quantifications. For this study’s Sprague–Dawley rat model, this 
Figure 4.  Predicted clinical absorbed organ doses from preclinical data for two PET radiotracers as a function 
of true measured clinical absorbed doses. Linear regressions plotted for various predictive dosimetry models of 
(a)  [18F]FDG and (b)  [18F]AlF-NOTA-OC. Resulted plotted excluding doses of the lower large intestinal wall. 
Data presented as Mean ± SEM. Legend: CI = Confidence interval, FBP = Filtered-back projection.
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modification universally improved the precision of dosimetry models. This is likely due to the fact that, unlike 
humans, rats have no  gallbladder25. Consequently, it is important to take into consideration species’ anatomical 
differences when assessing dosimetry of novel PET radiotracers.
In conclusion, the combined use of FBP reconstruction methods normalised to rodent:human organ data 
and the application of bias correction factor, as proposed in this study, represent an optimised model for transla-
tion of novel PET radiotracers to the clinic and can reduce attrition when developing novel PET radiotracers.
Materials and methods
Radiotracer preparation. No-carrier added aqueous  [18F]fluoride was produced via the 18O(p,n)18F 
nuclear reaction by irradiation of oxygen-18 enriched water on a GE PETtrace8 cyclotron. Analytical HPLC was 
performed on a Dionex UltiMate 300 using an Agilent Pursuit XRs 5 μm  C18 column (250 × 4 mm). All precur-
sors were purchased from Advanced Biochemical Compounds (ABX), apart from ENC2015 and ENC2018, 
which were manufactured as described  previously26. The structures of all radiotracers prepared in this study are 
shown in Supplementary Figure 1. 2-Deoxy-2-[18F]fluoro-d-glucose was prepared using the ABX Reagents Kit 
for the Synthesis Module GE TRACERlab MX FDG (ABX Advanced Biochemical Compounds Ltd.).
The radiosynthesis of the  Al18F-labelled peptides was carried out using an automated synthesis on a GE 
TRACERlab MX synthesiser. A disposable kit was assembled to allow the peptide conjugate to chelate aluminium 
fluoride and undergo purification using solid-phase extraction (SPE). Aqueous  [18F]fluoride (15‒25 GBq) was 
trapped on a SepPak QMA Light cartridge (Waters) and eluted with saline (0.30 mL). This was added to a 
reaction vessel charged with NOTA-peptide (0.012 mL, 2.0 mM solution in 0.1 M NaOAc buffer pH 4.0) and 
aluminium(III) chloride (0.0060 mL, 2.0 mM solution in 0.1 M NaOAc buffer pH 4.0) in acetonitrile (0.40 mL). 
The reaction mixture was then heated to 100 °C for 10 min. The reaction was diluted with water (25 mL) and 
transferred to a SepPak  C18 Plus Light cartridge, where it was washed with water (20 mL). The product was 
eluted with ethanol (1.5 mL), then water (5.5 mL) and diluted with saline (8.0 mL).  [18F]AlF-NOTA-octreotide 
was obtained in 1.4 ± 0.3% radiochemical yield (starting from 23 ± 9 GBq of activity, n = 4) with a radiochemical 
purity of > 99%.  [18F]AlF-NOTA-NOC was obtained in 6.4 ± 0.6% radiochemical yield (starting from 19 ± 7 GBq 
of activity, n = 3) with a radiochemical purity of > 99%.  [18F]AlF-NOTA-RGDfK was obtained in 11 ± 2% radio-
chemical yield (starting from 21 ± 2 GBq of  [18F]fluoride, n = 18) with a radiochemical purity of > 99%.  [18F]
ENC2015 radiochemical yield and purity were as previously  reported26.  [18F]ENC2018 was obtained in 10 ± 4% 
radiochemical yield (starting from 17 ± 0.4 GBq of  [18F]fluoride, n = 3) with a radiochemical purity of > 99%.
Animals. All experimental protocols were approved by an Animal Welfare and Ethical Review Body 
(AWERB) operating at the University of Edinburgh. The use of animals in this study was compliant with the 
University of Edinburgh’s institutional regulations and the Home Office’s guidance (Scientific Procedures) Act 
1986. Eighteen healthy adult male Sprague–Dawley rats (443.09 ± 83.06 g, mean body weight ± SD) were used in 
this study. All animals were maintained and housed at the Edinburgh Preclinical Imaging facility, University of 
Edinburgh, UK under standard 12 h light:12 h dark conditions with food and water available ad libitum.
Table 1.  Summary of correlation, mean bias, slope and 95% confidence intervals (CI) for  [18F]FDG and  [18F]
AlF-NOTA-OC using different preclinical dosimetry models versus clinical measurements.
Dosimetry model r2 Mean % bias Slope, mean ± SEM 95% CI slope
[18F]FDG
Adult male, non-normalised, FBP 0.754 111.1 2.111 ± 0.1083 1.898, 2.323
Adult male, normalised, FBP 0.855 40.44 0.5956 ± 0.02207 0.5523, 0.6388
Adult male, non-normalised, iterative 0.786 274.2 3.742 ± 0.1752 3.398, 4.085
Adult male, normalised, iterative 0.865 11.26 1.126 ± 0.03988 1.047, 1.204
Adult female, non-normalised, FBP 0.751 194.1 2.941 ± 0.1486 2.650, 3.233
Adult female, normalised, FBP 0.846 22.07 0.7793 ± 0.02916 0.7222, 0.8365
Adult female, non-normalised, iterative 0.785 425.1 5.251 ± 0.2412 4.779, 5.724
Adult female, normalised, iterative 0.886 47.87 1.487 ± 0.04684 1.395, 1.579
[18F]AlF-NOTA-OC
Adult male, non-normalised, FBP 0.4224 39.7 1.397 ± 0.2584 0.8753, 1.920
Adult male, normalised, FBP 0.5055 58.34 0.4166 ± 0.06515 0.2849, 0.5483
Adult male, non-normalised, iterative 0.436 156 2.560 ± 0.4603 1.629, 3.490
Adult male, normalised, iterative 0.5098 22.01 0.7799 ± 0.1209 0.5356, 1.024
Adult female, non-normalised, FBP 0.3996 89.7 1.897 ± 0.3588 1.173, 2.622
Adult female, normalised, FBP 0.4917 45.96 0.5404 ± 0.08479 0.3693, 0.7116
Adult female, non-normalised, iterative 0.4119 246.7 3.467 ± 0.6393 2.177, 4.758
Adult female, normalised, iterative 0.503 1.9 1.019 ± 0.1564 0.7037, 1.335
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pet studies. Image acquisition and reconstruction. On the day of imaging, rats were anaesthetised 
with 2‒2.5% isoflurane (50/50 oxygen/nitrous oxide, 1 L/min), then transferred to the preclinical PET/
CT scanner (nanoPET/CT, Mediso, Hungary) and placed in a supine position. A CT scan (semi-circular full 
Figure 5.  Bland–Altman plots assessing agreement between predicted clinical absorbed organ doses predicted 
from preclinical data for  [18F]FDG in all tissues excluding LLI. (a) Human predicted dose and FDG rat adult 
male TauUC FBP, (b) Human predicted dose and FDG rat adult male TauC FBP, (c) Human predicted dose and 
FDG rat adult female TauUC FBP, (d) Human predicted dose and FDG rat adult female TauUC FBP, (e) Human 
predicted dose and FDG rat adult male TauUC FBP Itr, (f) Human predicted dose and FDG rat adult male TauC 
FBP Itr (g) Human predicted dose and FDG rat adult female TauUC FBP Itr and (h) Human predicted dose and 
OC rat adult female TauC FBP Itr.
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Figure 6.  Bland–Altman plots assessing agreement between predicted clinical absorbed organ doses predicted 
from preclinical data for  [18F]AlF-NOTA-NOC in all tissues excluding LLI. (a) Human predicted dose and 
OC adult male TauUC FBP, (b) Human predicted dose and OC rat adult male TauC FBP, (c) Human predicted 
dose and OC rat adult female TauUC FBP, (d) Human predicted dose and OC rat adult female TauUC FBP, (e) 
Human predicted dose and OC rat adult male TauUC FBP Itr, (f) Human predicted dose and OC rat adult male 
TauC FBP Itr (g) Human predicted dose and FDG rat adult female TauUC FBP Itr and (h) Human predicted 
dose and OC rat adult female TauC FBP Itr.
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trajectory, maximum field of view, 480 projections, 50  kVp, 300  ms and 1:4 binning) was acquired for at-
tenuation correction. Animals were injected intravenously in the lateral tail vein with a bolus of one of six 
possible radiotracers (mean ± SD):  [18F]FDG 16.7 ± 5.53  MBq (0.3‒0.7  mL, n = 3),  [18F]AlF-NOTA-RGDfK 
25.16 ± 3.26 MBq (0.2‒0.3 mL, n = 3),  [18F]AlF-NOTA-NOC 15.65 ± 3.80 MBq (0.2‒0.5 mL, n = 3),  [18F]AlF-
NOTA-OC 16.48 ± 5.32 MBq (0.2‒0.3 mL, n = 3), ENC2015 17.37 ± 2.10 MBq (0.1‒0.5 mL, n = 3) and ENC2018 
16.49 ± 4.41 MBq (0.3‒0.4 mL, n = 3).
Immediately after radiotracer administration, a 240 min emission scan using 4 beds (50% overlap) was 
obtained using 3-dimensional 1:5 mode and re-binned as follows: 7 × 1 min, 2 × 5 min and 4 × 10 min. Throughout 
the PET/CT scanning session, animal temperature and respiration rate were monitored and controlled.
PET studies were reconstructed using filtered-back projection (FBP) and Mediso’s iterative Tera-Tomo 3D 
reconstruction algorithm with the following settings: 4 iterations, 6 subsets, full detector model, normal regu-
larization, spike filter on, voxel size 0.4 mm and 400‒600 keV energy window. PET data were corrected for 
randoms, scatter and attenuation.
Image processing. Reconstructed whole-body PET/CT images were imported into PMOD 3.8 software (PMOD 
Technologies, Switzerland) and static regions-of-interest (ROIs) were selected in approximately every third axial 
slice of source organs in animal subjects, which included the kidneys (left and right), urinary bladder, lungs 
(right and left), heart, brain, liver and intestine. Then, PMOD’s contours interpolation tool was used to interpo-
late ROIs for each organ into a corresponding volume-of-interest (VOI). A static cuboidal VOI was also drawn 
to include the animal whole-body.
Dosimetry analysis. Time-activity curves for each source organ, whole-body and remainder of the body were 
plotted. From 240 min to infinity min, only the physical half-life of fluorine-18 was used to estimate activity. 
Residence times (τ) were determined for each radiotracer in source organs, whole-body and remaining (any 
activity assigned to the whole-body but not assigned to a source organ). Each preclinical source organ’s τ was 
determined by calculating the area under its respective time-activity curve (activity normalised to the percent-
age maximum injected dose as a function of time) using the trapezoid method. Normalised τ of each radiotracer 
were obtained from the product of a compartment’s preclinical τ and a scaling factor (Supplementary Table 1), 
the latter of which was calculated using  (br/or)*(oh/bh) (adapted  from19), where  br and  bh were the body masses 
determined for rats and humans respectively;  or and  oh were the individual organ masses determined for rats and 
humans respectively. The  br used was 332.67 g (mean  of27–29) and the  bh used was 73,000 g for the adult male and 
60,000 g for the adult  female30. Both measured (non-normalised) and normalised τ were applied as kinetic data 
to human adult male and female phantoms from OLINDA/EXM 1.0 software (Vanderbilt University, Tennessee, 
USA); and OLINDA/EXM subsequently provided an output of the predicted absorbed organ doses and whole-
body effective doses for each phantom. From each individual animal, eight dosimetry models were constructed 
from all possible combinations of image reconstruction method (FBP or iterative), τ (non-normalised or nor-
malised to human organ masses), and sex of phantom (male or female).
Preclinical versus clinical bias analysis. Normalised and non-normalised τ for all six tested radiotracers in dif-
ferent organ compartments were plotted in a scatterplot of τ from iterative reconstructions as a function of those 
obtained from FBP reconstructions. Regression line slopes of FBP τ as a function of iterative τ were compared 
with a line-of-identity (slope = 1, i.e. perfect prediction of absorbed organ doses) by determining their 95% 
confidence intervals to assess if the prediction of residence times differed by reconstruction method. Addition-
ally, scatterplots of preclinically-predicted clinical absorbed organ doses from a given radiotracer as a function 
of the corresponding true clinical absorbed organ doses previously published per radiotracer were plotted for 
 [18F]FDG31 and  [18F]AlF-NOTA-OC32. A regression line was plotted for each radiotracer and each model’s mean 
percentage bias was calculated by defining the absolute value of 1 minus the mean slope of the model, multiplied 
by 100.
Graphical and statistical analysis. All graphs and statistical analyses were generated and performed in Graph-
Pad Prism 5.01 (GraphPad Software Inc., California, USA). One-way ANOVA followed by a Dunnett’s multiple 
comparison post-hoc test with  [18F]FDG as the control was used to determine which novel radiotracers’ bio-
distribution and dosimetry differed from  [18F]FDG in the same organs. All statistical tests used α = 0.05 as the 
measure for statistical significance. Bland–Altman plots were calculated as previously  described33,34.
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